Search results for "Adjuvant"

showing 10 items of 733 documents

Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of c…

2021

Abstract Introduction Sentinel lymph node biopsy (SLNB) after neoadjuvant therapy (NAT) in node-positive (N+) breast cancer patients at diagnosis remains a controversial issue, with no consensus on implementation or safety. Objectives We sought to assess the accuracy of SLNB after NAT in biopsy-proven N+ cases at diagnosis and the efficacy and accuracy of wire localization of the clipped node to improve results. Material and methods A cross-sectional diagnostic technique validation study in N+ patients following NAT was performed. The biopsy-proven affected lymph node was clipped at diagnosis. SLNB and axillary lymph node dissection (ALND) were performed in cases of clinical-radiological ly…

medicine.medical_specialtymedicine.medical_treatmentWire localizationSentinel lymph nodeBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerBiopsymedicineHumans030212 general & internal medicineLymph nodeNeoadjuvant therapyNeoplasm Stagingmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionMiddle Agedmedicine.diseaseSurgical InstrumentsNeoadjuvant Therapymedicine.anatomical_structureCross-Sectional Studies030220 oncology & carcinogenesisLymphatic MetastasisAxillaLymph Node ExcisionSurgeryNode (circuits)FemaleRadiologyLymph NodesSentinel Lymph NodebusinessThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
researchProduct

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct

Co-loading of finasteride and baicalin in phospholipid vesicles tailored for the treatment of hair disorders

2020

[EN] Hair loss affects a large number of people worldwide and it has a negative impact on the quality of life. Despite the availability of different drugs for the treatment of hair disorders, therapeutic options are still limited and scarcely effective. An innovative strategy to improve the efficacy of alopecia treatment is presented in this work. Finasteride, the only oral synthetic drug approved by Unites States Federal Drug Administration, was loaded in phospholipid vesicles. In addition, baicalin was co-loaded as an adjuvant. Their effect on hair growth was evaluatedin vitroandin vivo. Liposomes, hyalurosomes, glycerosomes and glycerol-hyalurosomes were manufactured by using a simple me…

medicine.medical_treatment02 engineering and technologyPharmacologyMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivomedicineAnimalsGeneral Materials SciencePhospholipidsFlavonoidsLiposomeintegumentary systemChemistryVesicleFinasteride021001 nanoscience & nanotechnologymedicine.diseaseMice Inbred C57BLHair loss030220 oncology & carcinogenesisHair DisorderQuality of LifeFinasteride0210 nano-technologyAdjuvantBaicalin
researchProduct

Comparison of adjuvant and adjuvant-free murine experimental asthma models

2009

Introduction The most widely used protocol for the induction of experimental allergic airway inflammation in mice involves sensitization by intraperitoneal (i.p.) injections of the antigen ovalbumin (OVA) used in conjunction with the adjuvant aluminium hydroxide (alum). Although adjuvants are frequently used, there are questions regarding the necessity of alum for murine asthma studies due to the non-physiological nature of this chemical. Objective The objective of this study was to compare experimental asthma phenotypes between adjuvant and adjuvant-free protocols of murine allergic airway inflammation in an attempt to develop a standardized alternative to adjuvant use. Method An adjuvant-…

medicine.medical_treatmentC57BL/6Aluminum HydroxideintraperitonealMicechemistry.chemical_compoundImmunology and AllergySensitizationMice Inbred BALB CbiologyAluminium hydroxiderespiratory systemPhenotypemedicine.anatomical_structuresubcutaneousFemaleBronchial HyperreactivityBALB/cAdjuvantInjections IntraperitonealOvalbuminInjections SubcutaneousImmunologyOriginal Articles:Experimental Models of Allergic Diseaseβ-galactosidaseSensitivity and Specificitycomplex mixturesBALB/cadjuvantAdjuvants ImmunologicAntigenmedicineAnimalsSkin TestsAsthmaAlumbusiness.industryanimal modelAllergensbeta-Galactosidasebiology.organism_classificationmedicine.diseaseAsthmabehaviourrespiratory tract diseasesMice Inbred C57BLDisease Models AnimalOvalbuminalumchemistryImmunologybiology.proteinbusinessClinical & Experimental Allergy
researchProduct

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct

Induction of Type-Specific Neutralizing Antibodies by Capsomeres of Human Papillomavirus Type 33

2001

Abstract The immunogenicity of capsomeres of human papillomavirus type 33 was evaluated in a dose–response analysis. Capsomeres were obtained free of capsids by expression of L1 carrying the single point mutation C427S. Neutralizing antibodies were detected using an in vitro pseudoinfection assay. Capsomeres induced type-specific, neutralizing antibodies in mice even in the absence of adjuvant. The neutralization titers of immune sera raised without adjuvant were 10- to 20-fold lower than those of antisera to virus-like particles, but virtually identical using Freund's adjuvant. These data indicate that capsomeres may substitute for virus-like particles in future vaccines when used with an …

medicine.medical_treatmentDose-Response Relationship ImmunologicEnzyme-Linked Immunosorbent AssayAntibodies ViralpapillomavirusNeutralizationMiceCapsidNeutralization Testsdose responseVirologymedicineAnimalsHumansPapillomaviridaeAntiserumMice Inbred BALB CbiologyImmunogenicityCapsomereVirionneutralizationvaccinationVirologyTiterCapsidbiology.proteincapsomeresImmunizationAntibodyAdjuvantVirology
researchProduct

The Potential Use of Resveratrol for Cancer Prevention.

2019

In addition to the traditional treatments of cancer and cancer prevention, the use of natural compounds, especially those found in food, should be considered. To clarify if resveratrol has the potential for cancer prevention and the possibility of use in therapy, the following must be taken into account: data from epidemiology, clinical protocol (case and control), preclinical studies (lab animals), use of established cell lines as models of cancer cells, test tube assays (enzymes activities), and requirements of nanotechnologies in order to discover new drugs to fight cancer. From this perspective and future expected advances, more information is needed such as improved efficacy, methods o…

medicine.medical_treatmentDrug Evaluation PreclinicalPharmaceutical ScienceReviewResveratrolresveratrolBioinformaticsChemopreventionAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinepreventionNeoplasmsDrug DiscoverymedicineAnimalsHumanscancerPhysical and Theoretical ChemistrySensitization030304 developmental biology0303 health sciencesmechanismsCancer preventionbusiness.industryOrganic ChemistryClinical Studies as TopicCancerDisease Managementmedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilitymedicine.anatomical_structurechemistryChemistry (miscellaneous)030220 oncology & carcinogenesisapproach strategiesCancer cellMolecular MedicineDisease Susceptibilitybusinessinnovative formulationsAdjuvantSignal TransductionMolecules (Basel, Switzerland)
researchProduct

Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1.

2000

Abstract Recently, the Th2-type cytokine IL-9 was identified by genetic mapping analyses as a key mediator that determines the susceptibility to asthma. This has been further supported by data from IL-9-transgenic mice in which the overexpression of IL-9 in the lung causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. In an accompanying paper, we demonstrate that murine bone marrow-derived mast cells (BMMC) after stimulation with either ionomycin, a combination of ionomycin and IL-1, or via IgE-Ag complexes and IL-1 are very potent producers of IL-9. Herein we show that a dramatic increase of IL-9 production is observed when BMMC activated with ionomycin/IL-…

medicine.medical_treatmentImmunologyEndogenyStem cell factorBone Marrow CellsBiologychemistry.chemical_compoundMiceAdjuvants ImmunologicmedicineImmunology and AllergyAnimalsMast CellsRNA MessengerReporter geneMice Inbred BALB CStem Cell FactorInterleukin-9TransfectionMolecular biologyInterleukin-10Interleukin 10medicine.anatomical_structureCytokinechemistryGene Expression RegulationIonomycinImmunologyBone marrow5' Untranslated RegionsInterleukin-1Journal of immunology (Baltimore, Md. : 1950)
researchProduct

Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.

2014

Multivalent synthetic vaccines were obtained by solid-phase synthesis of tumor-associated MUC1 glycopeptide antigens and their coupling to a Pam3 Cys lipopeptide through click reactions. These vaccines elicited immune responses in mice without the use of any external adjuvant. The vaccine containing four copies of a MUC1 sialyl-TN antigen showed a significant cluster effect. It induced in mice prevailing IgG2a antibodies, which bind to MCF-7 breast tumor cells and initiate the killing of these tumor cells by activation of the complement-dependent cytotoxicity complex.

medicine.medical_treatmentLipoproteinsEpitopes T-LymphocyteApoptosisCancer VaccinesCatalysisAntibodieschemistry.chemical_compoundMiceImmune systemAntigenmedicineAnimalsHumansAmino Acid Sequenceskin and connective tissue diseasesCytotoxicityMUC1Mice Inbred BALB CbiologyMucin-1GlycopeptidesLipopeptideGeneral ChemistryCombinatorial chemistryGlycopeptidechemistrybiology.proteinCancer researchMCF-7 CellsClick ChemistryRabbitsAntibodyAdjuvantAngewandte Chemie (International ed. in English)
researchProduct

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and prot…

2006

ABSTRACTRotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with…

medicine.medical_treatmentMESH : Cytokinesanimal diseasesMESH : Oligodeoxyribonucleotidesmedicine.disease_causeAntibodies ViralImmunoglobulin GMiceIntestinal mucosaMESH: RectumRotavirusMESH : FemaleMESH: AnimalsViralIntestinal MucosaInbred BALB C0303 health sciencesMice Inbred BALB CMESH: CytokinesMESH : Cholera ToxinMESH : Immunoglobulin A SecretoryMESH: Rotavirus Infections3. Good healthMESH : Rotavirus VaccinesVaccinationmedicine.anatomical_structureOligodeoxyribonucleotides[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : RectumMESH: Intestinal MucosaCytokinesMESH: VirionMESH: ImmunizationFemaleAdjuvantMESH : Antibodies ViralCholera ToxinImmunologyMESH: Mice Inbred BALB CSpleenchemical and pharmacologic phenomenaBiologyMicrobiologyMESH : Intestinal Mucosa[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Rotavirus VaccinesRotavirus InfectionsAntibodies03 medical and health sciencesImmune systemVirologyVaccines and Antiviral AgentsMESH : MicemedicineMESH : Rotavirus InfectionsMESH : VirionAnimalsMESH: MiceMESH : Mice Inbred BALB CMESH: Cholera Toxin030304 developmental biology030306 microbiologyRotavirus VaccinesRectumVirionMESH : Immunizationbiochemical phenomena metabolism and nutritionSecretoryVirologyImmunoglobulin AMESH: Immunoglobulin A SecretoryImmunizationInsect ScienceImmunologyImmunoglobulin A Secretorybiology.proteinMESH: OligodeoxyribonucleotidesbacteriaImmunizationMESH : AnimalsMESH: FemaleMESH: Antibodies Viral
researchProduct